Humacyte, INC Form 4 insider transactions

Humacyte's CEO, Laura Niklason, reported a purchase of 1,222 shares of common stock at $6.545 per share on August 29, 2024, while also disclosing beneficial ownership through various entities.

Director Brady W. Dougan reports a transaction involving Humacyte, Inc. common stock.

Brady W. Dougan, a director at Humacyte, Inc., sold shares of common stock between August 27 and August 29, 2024, to pay down leverage and provide investors an opportunity to acquire shares.

Humacyte's CEO, Laura Niklason, indirectly sold shares through Ayabudge LLC, an entity controlled by Brady W. Dougan, to pay down leverage and provide investors an opportunity to acquire shares.

Humacyte's CFO, Dale A. Sander, exercised stock options and sold shares of common stock on August 27, 2024.

Director Michael T. Constantino reports the acquisition and disposal of Humacyte, Inc. common stock on August 15, 2024.

Director Kathleen Sebelius reports the acquisition of stock options and the exercise of previously held options in Humacyte, Inc.

Susan Richards Windham-Bannister, a director of Humacyte, Inc., acquired 50,000 stock options on June 13, 2024, exercisable over a four-year period.

Director Max N. Wallace of Humacyte, Inc. reports the acquisition of 50,000 stock options exercisable over a period beginning June 13, 2025.

Director Diane Seimetz reports the acquisition of 50,000 stock options in Humacyte, Inc. on June 13, 2024.

Director Todd Pope reports the acquisition of 50,000 stock options in Humacyte, Inc. on June 13, 2024.

Humacyte's CEO, Laura Niklason, reported the acquisition of stock options exercisable for 50,000 shares of common stock, according to a Form 4 filing with the SEC.

Keith Anthony Jones, a director of Humacyte, Inc., acquired 75,000 stock options on June 13, 2024, exercisable over a four-year period.

Director Charles Bruce Green reports acquisition of 50,000 Humacyte stock options on June 13, 2024.

Director Brady W. Dougan acquired 50,000 stock options in Humacyte, Inc. on June 13, 2024.

Director Michael T. Constantino reports acquisition of 50,000 stock options in Humacyte, Inc.

Director Emery N. Brown acquired 50,000 stock options in Humacyte, Inc. on June 13, 2024.

John Philip Bamforth, a director of Humacyte, Inc., acquired 75,000 stock options on June 13, 2024, exercisable over a four-year period.

Humacyte's CEO, Laura Niklason, indirectly sold shares through Ayabudge LLC and directly held shares in private transactions, while maintaining significant beneficial ownership.

Brady W. Dougan, a director at Humacyte, Inc., executed multiple sales of common stock, both in private transactions and on the open market, to manage leverage and facilitate investor acquisition.

Humacyte's CEO, Laura Niklason, reported purchasing shares to offset a sale by her spouse's entity, Ayabudge LLC, and has remitted profits to the issuer to resolve potential liability under Section 16(b) of the Securities Exchange Act.

Director Brady W. Dougan reports a purchase of Humacyte, Inc. common stock by his spouse, along with adjustments to his beneficial ownership.

Laura Niklason, CEO of Humacyte, indirectly sold shares of common stock through Ayabudge LLC to pay down leverage and facilitate investor acquisition.

Brady W. Dougan, a director at Humacyte, Inc., sold shares of common stock through Ayabudge LLC between May 31 and June 4, 2024, to pay down leverage and provide investors an opportunity to acquire shares.

Laura Niklason, CEO of Humacyte, reports a recent stock purchase and a transfer of shares to The Niklason Living Trust.

Director Brady W. Dougan reports purchasing 2,050 shares of Humacyte, Inc. common stock at $7.37 per share and changes in beneficial ownership due to a trust transfer.

Humacyte's Chief Operating Officer, Heather Ledbetter Prichard, recently engaged in multiple transactions involving the company's common stock and stock options.

Director Max N. Wallace reports purchasing additional shares of Humacyte, Inc. through IRA accounts.

Charles Bruce Green, a director of Humacyte, Inc., exercised stock options and disposed of 600 shares of common stock on May 20, 2024.

Charles Bruce Green, a director at Humacyte, Inc., executed stock options to acquire 600 shares of common stock at $4.09 on May 17, 2024.